Menu Search
Equities

Bide Pharmatech Co Ltd

688073:SHH

Bide Pharmatech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)29.30
  • Today's Change-0.62 / -2.07%
  • Shares traded330.12k
  • 1 Year change-50.86%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Bide Pharmatech Co Ltd had net income fall -24.94% from 145.97m to 109.57m despite a 30.94% increase in revenues from 833.83m to 1.09bn. An increase in the cost of goods sold as a percentage of sales from 56.52% to 61.67% was a component in the falling net income despite rising revenues.
Gross margin38.92%
Net profit margin6.96%
Operating margin8.42%
Return on assets3.26%
Return on equity3.86%
Return on investment3.73%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Bide Pharmatech Co Ltd fell by 230.39m. Cash Flow from Investing was negative at 28.87m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 57.39m for operations while cash used for financing totalled 138.31m.
Cash flow per share--
Price/Cash flow per share--
Book value per share21.73
Tangible book value per share21.69
More ▼

Balance sheet in CNYView more

Bide Pharmatech Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio7.35
Quick ratio5.04
Total debt/total equity0.045
Total debt/total capital0.043
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.